Research across Cancer
Related studies from across the Cancer family.
Enzalutamide added to ADT improves survival in APIC-negative metastatic hormone-sensitive prostate cancer
Trial shows enzalutamide helps specific patients with prostate cancer
This randomized controlled trial analyzed 492 patients with metastatic hormone-sensitive prostate cancer to evaluate the impact of the APIC …
A new analysis shows that a specific biomarker can help doctors identify which prostate cancer patients may benefit most from enzalutamide t…
Trastuzumab Deruxtecan Management of HER2 Positive Metastatic Breast Cancer with Visceral Crisis
Newer drug shows promise for advanced breast cancer and liver issues
A case report highlights the efficacy of trastuzumab deruxtecan in managing visceral crisis in HER2-positive metastatic breast cancer.
A new treatment approach may help patients with advanced breast cancer who are facing a sudden, serious crisis in their liver function.
Rezvilutamide plus ADT with efavirenz-based ART yields PSA decline in one HIV-positive mHSPC patient
Rezvilutamide Shows Promise for Prostate Cancer in HIV Patients
This is a single-patient case report describing rezvilutamide plus androgen deprivation therapy in an HIV-positive patient with high-volume …
A single patient with both HIV and advanced prostate cancer showed significant improvement after starting a specific combination of treatmen…
Evaluating AI and Manual Stromal Immune Cell Quantification in HER2 Positive Breast Cancer
AI tools help predict outcomes for HER2-positive breast cancer
This Phase 3 analysis evaluates how manual, digital, and AI-based sTIL quantification impact prognostic and predictive outcomes in HER2+ bre…
New analysis shows that AI and manual counts of immune cells can help predict how well patients with HER2-positive breast cancer respond to …
Meridian Sinew Tuina significantly reduces upper limb circumference and pain in breast cancer-related lymphedema
Meridian Sinew Tuina May Help Manage Breast Cancer Lymphedema
This meta-analysis evaluated the impact of Meridian Sinew Tuina on patients with breast cancer-related lymphedema. The analysis found signif…
A specialized deep tissue massage technique called Meridian Sinew Tuina shows promise in reducing swelling and pain for those with breast ca…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
Lead-in therapy may reduce severe low white blood cell counts
This post hoc analysis of a phase 3 trial and real-world validation study evaluated lead-in androgen-deprivation therapy (ADT) for patients …
A new look at clinical data suggests that a lead-in hormone treatment can help prevent serious low white blood cell counts in prostate cance…
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.